

Contact: CEOcast, Inc.
Gary Nash
Investor Relations
212-732-4300
gnash@ceocast.com

ImmunoCellular Therapeutics to Present Clinical Data on ICT-107 at Leading Cancer Stem Cells Conference

LOS ANGELES, CA – March 23, 2010 – ImmunoCellular Therapeutics, Ltd. (OTC.BB: IMUC) , announced today that Manish Singh, Ph.D., President and CEO, will be presenting at the Cancer Stem Cells Conference, a leading industry event, on Wednesday, March 24th at 2:00 p.m. eastern time. At the event, Dr. Singh will present clinical data on ICT-107 and developmental plans for the candidate, preclinical data on ICT-121 and the mechanism of dendritic cell based vaccination, during a session entitled, “Translating Research into Drug Development I.”

Also presenting during the session will be executives from OncoMed, Geron, and Micromet. The conference, hosted by Biorbis, a division of Hanson Wade, will take place at Le Meridien Hotel in Cambridge, MA.

About ImmunoCellular Therapeutics

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently completed a Phase I trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. The Company is planning to initiate a multicenter phase II study in the second half of 2010. The Company's "off the shelf" therapeutic vaccine product candidate (ICT-121) targeting cancer stem cells for multiple cancer indications is targeted by IMUC to enter clinical trials for glioblastoma during the second half of 2010. IMUC has entered into a research and license option deal with the Roche Group for one of the Company's monoclonal antibody product candidates for the diagnosis and treatment of ovarian cancer and multiple myeloma, which provides for potential licensing and milestone payments of \$32MM and royalties if the Roche Group exercises its option and commercializes this antibody technology for multiple indications. IMUC is in pre-clinical development of another monoclonal antibody product candidate for the treatment of small cell lung cancer and pancreatic cancer, and is also evaluating its platform technology for monoclonal antibody discovery to target cancer stem cells. To learn more about IMUC, please visit www.imuc.com.

About Biorbis Cancer Stem Cell Conference

Biorbis' Cancer Stem Cell Conference is the world's first and only industry-focused cancer stem cell meeting providing a unique opportunity for oncology business/research leaders and scientists to assess the potential of cancer stem cells for your business and research. The conference will feature presentations from more than 25 leading experts in cancer stem cell research and drug development,

panel discussions on business issues and trends within the industry, and a host of networking opportunities. For more information, visit www.biorbis.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation, the risks associated with the potential inability to obtain licenses from third parties that will be needed to commercialize ICT-107 in many major commercial territories; the potential inability to secure a partner to fund development and marketing of ICT-107; the risk that future trials of ICT-107, if any, do not confirm the safety and efficacy data generated in the Phase I trial; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with obtaining a patent that provides commercially significant protection for ICT-107; the risk of encountering substantial delays in completing or being unable to successfully complete the pre-clinical testing necessary before initiating clinical testing of ICT-121; and the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages and to continue IMUC's operations. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

###